121 related articles for article (PubMed ID: 20932681)
1. Use of the Charlson combined comorbidity index to predict postradiotherapy quality of life for prostate cancer patients.
Wahlgren T; Levitt S; Kowalski J; Nilsson S; Brandberg Y
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):997-1004. PubMed ID: 20932681
[TBL] [Abstract][Full Text] [Related]
2. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer.
Wahlgren T; Nilsson S; Lennernäs B; Brandberg Y
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):662-70. PubMed ID: 17499452
[TBL] [Abstract][Full Text] [Related]
3. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
[TBL] [Abstract][Full Text] [Related]
5. Cross-sectional survey of long-term quality of life after radical perineal prostatectomy.
Yang BK; Crisci A; Young MD; Silverstein AD; Peterson BL; Dahm P
Urology; 2005 Jan; 65(1):120-5. PubMed ID: 15667876
[TBL] [Abstract][Full Text] [Related]
6. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
7. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer.
Roeloffzen EM; Lips IM; van Gellekom MP; van Roermund J; Frank SJ; Battermann JJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1054-60. PubMed ID: 20097486
[TBL] [Abstract][Full Text] [Related]
9. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer.
Galalae RM; Loch T; Riemer B; Rzehak P; Küchler T; Kimmig B; Kovács G
Strahlenther Onkol; 2004 Sep; 180(9):582-9. PubMed ID: 15378189
[TBL] [Abstract][Full Text] [Related]
11. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
Truong PT; Berthelet E; Lee JC; Petersen R; Lim JT; Gaul CA; Pai H; Blood P; Ludgate CM
Can J Urol; 2006 Jun; 13(3):3139-46. PubMed ID: 16813705
[TBL] [Abstract][Full Text] [Related]
13. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
14. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
16. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
17. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study.
Borggreven PA; Verdonck-de Leeuw IM; Muller MJ; Heiligers ML; de Bree R; Aaronson NK; Leemans CR
Eur Arch Otorhinolaryngol; 2007 Jun; 264(6):651-7. PubMed ID: 17273840
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
20. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE.
Downs TM; Sadetsky N; Pasta DJ; Grossfeld GD; Kane CJ; Mehta SS; Carroll PR; Lubeck DP
J Urol; 2003 Nov; 170(5):1822-7. PubMed ID: 14532784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
